SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 144 - Report of proposed sale of securities:
SEC Accession No. 0000950170-24-032447
Filing Date
2024-03-15
Accepted
2024-03-15 21:45:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3517
  Complete submission text file 0000950170-24-032447.txt   5480
Mailing Address 1701-1702, CHINA CENTRAL OFFICE TOWER 1 NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT BEIJING F4 100025
Business Address 1701-1702, CHINA CENTRAL OFFICE TOWER 1 NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT BEIJING F4 100025 86 10 6561 8789
CASI Pharmaceuticals, Inc. (Subject) CIK: 0001962738 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-41666 | Film No.: 24756781
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O PANACEA VENTURE, NO. 5, LANE 1350 FUXING MIDDLE ROAD SHANGHAI F4 200031
Business Address C/O PANACEA VENTURE, NO. 5, LANE 1350 FUXING MIDDLE ROAD SHANGHAI F4 200031 86 21 60252100
Panacea Innovation Ltd (Reporting) CIK: 0002010692 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 144